Breaking News Instant updates and real-time market news.

ICPT

Intercept

$70.79

0.68 (0.97%)

07:04
04/13/18
04/13
07:04
04/13/18
07:04

Intercept announces data from liver biopsy substudy of POISE Phase 3 trial

Intercept Pharmaceuticals announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial suggesting that long-term OCA treatment in patients with PBC was associated with reversal or stabilization of fibrosis and cirrhosis. The data are being presented at the International Liver Congress 2018, the 53rd Annual Meeting of the European Association for the Study of the Liver, in Paris, France, from April 11-15, 2018. OCA is not currently indicated for the reversal of fibrosis or cirrhosis in patients with PBC. Prior longitudinal biopsy studies have shown that patients who are not treated with, or have an inadequate response to, ursodeoxycholic acid, the current standard of care, are at significantly higher risk of fibrosis progression, liver failure, transplant and death. Liver biopsy is not the standard of care in PBC and difficult to obtain in clinical trials. In this voluntary substudy of the POISE Phase 3 trial, paired biopsies adequate for analysis were obtained for 13 patients, all of whom had liver fibrosis or cirrhosis at baseline. After three years of treatment with OCA, the majority of patients improved or maintained histological fibrosis stage, while two patients experienced one stage progression. Of the four patients with cirrhosis at baseline, all showed reversal by at least one stage, and three improved to fibrosis without cirrhosis. Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE Phase 3 substudy. Nine patients experienced pruritus in the substudy, an incidence consistent with the rate observed in the broader study population. A total of five serious adverse events in five patients were reported. All serious adverse events were considered unlikely to be related, or not related, to OCA. A separate poster, "Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis," presented at the International Liver Congress provided additional results from the open-label extension of the POISE trial. Sustained improvements in ALP were observed through three years of OCA therapy, with similar improvements seen for GGT, ALT and AST. Mean total bilirubin remained below baseline throughout the three-year open-label period. The most common adverse event observed with OCA therapy was pruritus, resulting in the discontinuation of seven patients during the open-label extension treatment phase. An additional poster, "Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202," assessed changes in total bilirubin observed in the POISE Phase 3 trial and two Phase 2 trials. The analysis, which included patients with total bilirubin greater than or equal to0.67 times the upper limit of normal at baseline, found that total bilirubin increased after 12 months of placebo treatment and decreased after 12 months of treatment with OCA. In the double-blind phase of POISE, 14% of placebo-treated and 78% of OCA-treated patients with abnormal total bilirubin at baseline attained normal levels after 12 months. Further, of 10 placebo-treated and 20 OCA-treated patients with normal total bilirubin at baseline, 60% of placebo-treated and 15% of OCA-treated patients worsened to abnormal total bilirubin after 12 months. Per EASL clinical guidelines, increasing bilirubin levels - even within the normal range - indicate progressive disease and are strongly associated with adverse clinical outcomes.

  • 13

    Apr

  • 20

    Apr

  • 08

    May

  • 21

    May

ICPT Intercept
$70.79

0.68 (0.97%)

03/28/18
LEER
03/28/18
NO CHANGE
Target $16
LEER
Outperform
More differentiating data at EASL can continue CymaBay momentum, says Leerink
Leerink analyst Joseph Schwartz expects a 6-month Phase 2 study update for CymaBay's (CBAY) seladelpar in primary biliary cholangitis to be reported at the International Liver Congress. The analyst notes CymaBay stock has enjoyed strong momentum since the preliminary 12-week data and he remains optimistic that seladelpar's profile will continue to look differentiated from Intercept's (ICPT) Ocaliva when it comes to safety/tolerability and efficacy in the second-line PBC treatment setting. The analyst reiterates an Outperform rating and $16 price target on CymaBay's shares.
02/13/18
WELS
02/13/18
NO CHANGE
Target $57
WELS
Market Perform
Intercept price target lowered to $57 from $62 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.
02/12/18
DBAB
02/12/18
NO CHANGE
Target $103
DBAB
Buy
Intercept study initiation a positive, says Deutsche Bank
Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.
02/07/18
GSCO
02/07/18
DOWNGRADE
Target $45
GSCO
Sell
Intercept downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.

TODAY'S FREE FLY STORIES

01:45
01/24/19
01/24
01:45
01/24/19
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

JNPR

Juniper

$27.99

0.16 (0.57%)

21:01
01/23/19
01/23
21:01
01/23/19
21:01
Hot Stocks
Juniper selected by BroadBand Tower to build Japan 5G data center »

Juniper Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 07

    Feb

PTC

PTC

$84.73

-1.14 (-1.33%)

20:28
01/23/19
01/23
20:28
01/23/19
20:28
Recommendations
PTC analyst commentary at MUFG »

PTC price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UNP

Union Pacific

$154.20

-0.8 (-0.52%)

, BMY

Bristol-Myers

$49.92

0.21 (0.42%)

20:25
01/23/19
01/23
20:25
01/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

UNP

Union Pacific

$154.20

-0.8 (-0.52%)

BMY

Bristol-Myers

$49.92

0.21 (0.42%)

LUV

Southwest

$50.97

0.425 (0.84%)

MKC

McCormick

$139.03

0.31 (0.22%)

FCX

Freeport McMoRan

$12.30

-0.08 (-0.65%)

GWW

Grainger

$297.12

-3.29 (-1.10%)

AAL

American Airlines

$31.57

-1.18 (-3.60%)

HBAN

Huntington Bancshares

$13.56

0.05 (0.37%)

TXT

Textron

$49.19

0.76 (1.57%)

JBLU

JetBlue

$17.23

-0.13 (-0.75%)

AEP

American Electric

$77.00

0.65 (0.85%)

TAL

TAL Education

$31.21

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 07

    Feb

  • 18

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

ADTN

Adtran

$12.25

0.49 (4.17%)

20:14
01/23/19
01/23
20:14
01/23/19
20:14
Earnings
Adtran reports Q4 adjusted EPS (12c), consensus (3c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MSFT

Microsoft

$106.77

0.91 (0.86%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

20:10
01/23/19
01/23
20:10
01/23/19
20:10
Periodicals
China blocks Microsoft's Bing search engine, FT reports »

China regulators have…

MSFT

Microsoft

$106.77

0.91 (0.86%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

BIDU

Baidu

$163.22

2.81 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

EBAY

eBay

$32.62

-0.3 (-0.91%)

20:03
01/23/19
01/23
20:03
01/23/19
20:03
Recommendations
eBay analyst commentary at Baird »

eBay should consider…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

CLR

Continental Resources

$45.30

-0.27 (-0.59%)

20:00
01/23/19
01/23
20:00
01/23/19
20:00
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

APY

Apergy

$33.20

-0.35 (-1.04%)

19:55
01/23/19
01/23
19:55
01/23/19
19:55
Initiation
Apergy initiated at Gabelli »

Apergy initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 19

    Feb

AMZN

Amazon.com

$1,641.50

7.35 (0.45%)

19:15
01/23/19
01/23
19:15
01/23/19
19:15
Hot Stocks
AWS unveils Amazon WorkLink solution »

Amazon Web Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 28

    Jan

  • 31

    Jan

  • 04

    Feb

  • 20

    Feb

  • 03

    Mar

SMBK

SmartFinancial

$18.35

0.21 (1.16%)

19:08
01/23/19
01/23
19:08
01/23/19
19:08
Earnings
SmartFinancial reports Q4 operating EPS 43c, consensus 37c »

SmartFinancial Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MLRYY

Mail.Ru Group

$0.00

(0.00%)

19:05
01/23/19
01/23
19:05
01/23/19
19:05
Downgrade
Mail.Ru Group rating change at Goldman Sachs »

Mail.Ru Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$152.03

-0.1 (-0.07%)

18:58
01/23/19
01/23
18:58
01/23/19
18:58
Periodicals
Zhongnan Group to buy Alibaba-backed EasyHome for CNY38B, Bloomberg says »

Alibaba owns a 15% stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 03

    Mar

  • 04

    Mar

JPM

JPMorgan

$102.72

-0.23 (-0.22%)

18:55
01/23/19
01/23
18:55
01/23/19
18:55
Periodicals
JPMorgan exec says private bank expands ops in Mexico, Reuters says »

JPMorgan's private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SLM

Sallie Mae

$9.49

0.1 (1.07%)

, XLNX

Xilinx

$89.55

-0.89 (-0.98%)

18:53
01/23/19
01/23
18:53
01/23/19
18:53
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: SLM…

SLM

Sallie Mae

$9.49

0.1 (1.07%)

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

AZPN

Aspen Technology

$89.08

0.22 (0.25%)

LRCX

Lam Research

$139.24

-0.58 (-0.41%)

URI

United Rentals

$115.98

-2.21 (-1.87%)

TER

Teradyne

$31.93

0.13 (0.41%)

VAR

Varian Medical

$126.83

1.57 (1.25%)

CP

Canadian Pacific

$195.71

0.02 (0.01%)

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

F

Ford

$8.34

-0.17 (-2.00%)

BGG

Briggs & Stratton

$13.73

-0.46 (-3.24%)

PTC

PTC

$84.73

-1.14 (-1.33%)

CTXS

Citrix

$108.64

0.4 (0.37%)

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

FFIV

F5 Networks

$159.65

2.5 (1.59%)

CCI

Crown Castle

$110.28

1.13 (1.04%)

NCNA

NuCana

$14.37

-0.38 (-2.58%)

ADXS

Advaxis

$0.32

-0.0283 (-8.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 11

    Feb

  • 14

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

  • 25

    Apr

  • 28

    May

  • 24

    Jul

  • 23

    Oct

  • 25

    Jan

FB

Facebook

$144.35

-3.45 (-2.33%)

18:41
01/23/19
01/23
18:41
01/23/19
18:41
Periodicals
Advocacy groups pushing FTC to force Facebook breakup, WSJ says »

Multiple advocacy groups…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

18:38
01/23/19
01/23
18:38
01/23/19
18:38
Periodicals
Devs say Google's Chrome proposal threatens ad blockers, Bloomberg says »

Developers are…

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

FCPT

Four Corners Property Trust

$26.58

-0.09 (-0.34%)

, BLMN

Bloomin' Brands

$19.15

0.08 (0.42%)

18:36
01/23/19
01/23
18:36
01/23/19
18:36
Recommendations
Four Corners Property Trust, Bloomin' Brands analyst commentary  »

Four Corners Property…

FCPT

Four Corners Property Trust

$26.58

-0.09 (-0.34%)

BLMN

Bloomin' Brands

$19.15

0.08 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

BAC

Bank of America

$28.91

-0.18 (-0.62%)

18:11
01/23/19
01/23
18:11
01/23/19
18:11
Periodicals
Bank of America appoints Mike Joo as investment operating chief, Reuters says »

Head of global rates and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 03

    Mar

F

Ford

$8.34

-0.17 (-2.00%)

18:08
01/23/19
01/23
18:08
01/23/19
18:08
Hot Stocks
Ford says Russian alliance 'under review' »

Says won't have to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CHMG

Chemung Financial

$41.99

-0.11 (-0.26%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Earnings
Chemung Financial reports Q4 EPS $1.18, consensus $1.04 »

Reports Q4 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

18:03
01/23/19
01/23
18:03
01/23/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 2019 will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:01
01/23/19
01/23
18:01
01/23/19
18:01
Hot Stocks
Ford says 2018 auto EBIT benefited from improvement of market factors »

Says auto EBIT in 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:56
01/23/19
01/23
17:56
01/23/19
17:56
Hot Stocks
Henry Schein falls after saying it will not be key supplier to VCA,Pet Partners »

Shares of Henry Schein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.